journal
Journals CA: a Cancer Journal for Clini...

CA: a Cancer Journal for Clinicians

https://read.qxmd.com/read/38703384/evolution-of-community-outreach-and-engagement-at-national-cancer-institute-designated-cancer-centers-an-evolving-journey
#1
REVIEW
Sarah A Pohl, Barry A Nelson, Tanjeena R Patwary, Salina Amanuel, Edward J Benz, Christopher S Lathan
Cancer mortality rates have declined during the last 28 years, but that process is not equitably shared. Disparities in cancer outcomes by race, ethnicity, socioeconomic status, sexual orientation and gender identity, and geographic location persist across the cancer care continuum. Consequently, community outreach and engagement (COE) efforts within National Cancer Institute-Designated Cancer Center (NCI-DCC) catchment areas have intensified during the last 10 years as has the emphasis on COE and catchment areas in NCI's Cancer Center Support Grant applications...
May 4, 2024: CA: a Cancer Journal for Clinicians
https://read.qxmd.com/read/38685134/critical-updates-in-neuroendocrine-tumors-version-9-american-joint-committee-on-cancer-staging-system-for-gastroenteropancreatic-neuroendocrine-tumors
#2
JOURNAL ARTICLE
Aman Chauhan, Kelley Chan, Thorvardur R Halfdanarson, Andrew M Bellizzi, Guido Rindi, Dermot O'Toole, Phillip S Ge, Dhanpat Jain, Arvind Dasari, Daniel A Anaya, Emily Bergsland, Erik Mittra, Alice C Wei, Thomas A Hope, Ayse T Kendi, Samantha M Thomas, Sherlonda Flem, James Brierley, Elliot A Asare, Kay Washington, Chanjuan Shi
The American Joint Committee on Cancer (AJCC) staging system for all cancer sites, including gastroenteropancreatic neuroendocrine tumors (GEP-NETs), is meant to be dynamic, requiring periodic updates to optimize AJCC staging definitions. This entails the collaboration of experts charged with evaluating new evidence that supports changes to each staging system. GEP-NETs are the second most prevalent neoplasm of gastrointestinal origin after colorectal cancer. Since publication of the AJCC eighth edition, the World Health Organization has updated the classification and separates grade 3 GEP-NETs from poorly differentiated neuroendocrine carcinoma...
April 29, 2024: CA: a Cancer Journal for Clinicians
https://read.qxmd.com/read/38652221/cancer-diagnosis-and-treatment-in-working-age-adults-implications-for-employment-health-insurance-coverage-and%C3%A2-financial-hardship-in-the-united-states
#3
JOURNAL ARTICLE
K Robin Yabroff, Joanna F Doran, Jingxuan Zhao, Fumiko Chino, Ya-Chen Tina Shih, Xuesong Han, Zhiyuan Zheng, Cathy J Bradley, Monica F Bryant
The rising costs of cancer care and subsequent medical financial hardship for cancer survivors and families are well documented in the United States. Less attention has been paid to employment disruptions and loss of household income after a cancer diagnosis and during treatment, potentially resulting in lasting financial hardship, particularly for working-age adults not yet age-eligible for Medicare coverage and their families. In this article, the authors use a composite patient case to illustrate the adverse consequences of cancer diagnosis and treatment for employment, health insurance coverage, household income, and other aspects of financial hardship...
April 23, 2024: CA: a Cancer Journal for Clinicians
https://read.qxmd.com/read/38625753/not-only-a-western-world-issue-cancer-incidence-in-younger-individuals-in-the-united-arab-emirates
#4
EDITORIAL
Humaid O Al-Shamsi, Khaled M Musallam
No abstract text is available yet for this article.
April 16, 2024: CA: a Cancer Journal for Clinicians
https://read.qxmd.com/read/38572764/global-cancer-statistics-a-healthy-population-relies-on-population-health
#5
EDITORIAL
Natia Jokhadze, Arunangshu Das, Don S Dizon
No abstract text is available yet for this article.
April 4, 2024: CA: a Cancer Journal for Clinicians
https://read.qxmd.com/read/38572751/global-cancer-statistics-2022-globocan-estimates-of-incidence-and-mortality-worldwide-for-36-cancers-in-185-countries
#6
JOURNAL ARTICLE
Freddie Bray, Mathieu Laversanne, Hyuna Sung, Jacques Ferlay, Rebecca L Siegel, Isabelle Soerjomataram, Ahmedin Jemal
This article presents global cancer statistics by world region for the year 2022 based on updated estimates from the International Agency for Research on Cancer (IARC). There were close to 20 million new cases of cancer in the year 2022 (including nonmelanoma skin cancers [NMSCs]) alongside 9.7 million deaths from cancer (including NMSC). The estimates suggest that approximately one in five men or women develop cancer in a lifetime, whereas around one in nine men and one in 12 women die from it. Lung cancer was the most frequently diagnosed cancer in 2022, responsible for almost 2...
April 4, 2024: CA: a Cancer Journal for Clinicians
https://read.qxmd.com/read/38571300/cytoreductive-surgery-systemic-treatment-genetic-evaluation-and-patient-perspective-in-a-young-adult-with-metastatic-renal-cell-carcinoma
#7
JOURNAL ARTICLE
Edouard H Nicaise, Ahmet Yildirim, Swapnil Sheth, Ellen Richter, Mani A Daneshmand, Shishir K Maithel, Kenneth Ogan, Mehmet A Bilen, Viraj A Master
No abstract text is available yet for this article.
April 3, 2024: CA: a Cancer Journal for Clinicians
https://read.qxmd.com/read/38517471/multicancer-detection-tests-what-we-know-and-what-we-don-t-know
#8
EDITORIAL
Sam M Hanash, Peter P Yu
No abstract text is available yet for this article.
March 22, 2024: CA: a Cancer Journal for Clinicians
https://read.qxmd.com/read/38517462/cancer-screening-with-multicancer-detection-tests-a-translational-science-review
#9
REVIEW
Wendy S Rubinstein, Christos Patriotis, Anthony Dickherber, Paul K J Han, Hormuzd A Katki, Elyse LeeVan, Paul F Pinsky, Philip C Prorok, Amanda L Skarlupka, Sarah M Temkin, Philip E Castle, Lori M Minasian
Multicancer detection (MCD) tests use a single, easily obtainable biospecimen, such as blood, to screen for more than one cancer concurrently. MCD tests can potentially be used to improve early cancer detection, including cancers that currently lack effective screening methods. However, these tests have unknown and unquantified benefits and harms. MCD tests differ from conventional cancer screening tests in that the organ responsible for a positive test is unknown, and a broad diagnostic workup may be necessary to confirm the location and type of underlying cancer...
March 22, 2024: CA: a Cancer Journal for Clinicians
https://read.qxmd.com/read/38363123/erratum-to-cancer-statistics-2024
#10
(no author information available yet)
No abstract text is available yet for this article.
February 16, 2024: CA: a Cancer Journal for Clinicians
https://read.qxmd.com/read/38329372/neoadjuvant-chemotherapy-for-advanced-oral-cavity-cancer
#11
JOURNAL ARTICLE
Dan Yaniv, Tanguy Y Seiwert, Danielle N Margalit, Michelle D Williams, Carly E A Barbon, Rene D Largo, Jon A Smith, Neil D Gross
No abstract text is available yet for this article.
February 8, 2024: CA: a Cancer Journal for Clinicians
https://read.qxmd.com/read/38279898/becoming-the-new-editor-for-ca-the-future-is-now
#12
EDITORIAL
Don S Dizon
No abstract text is available yet for this article.
January 27, 2024: CA: a Cancer Journal for Clinicians
https://read.qxmd.com/read/38230825/cancer-statistics-2024-all-hands-on-deck
#13
EDITORIAL
Don S Dizon, Arif H Kamal
No abstract text is available yet for this article.
January 17, 2024: CA: a Cancer Journal for Clinicians
https://read.qxmd.com/read/38230766/cancer-statistics-2024
#14
JOURNAL ARTICLE
Rebecca L Siegel, Angela N Giaquinto, Ahmedin Jemal
Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths in the United States and compiles the most recent data on population-based cancer occurrence and outcomes using incidence data collected by central cancer registries (through 2020) and mortality data collected by the National Center for Health Statistics (through 2021). In 2024, 2,001,140 new cancer cases and 611,720 cancer deaths are projected to occur in the United States. Cancer mortality continued to decline through 2021, averting over 4 million deaths since 1991 because of reductions in smoking, earlier detection for some cancers, and improved treatment options in both the adjuvant and metastatic settings...
January 17, 2024: CA: a Cancer Journal for Clinicians
https://read.qxmd.com/read/38174605/interpreting-and-integrating-genomic-tests-results-in-clinical-cancer-care-overview-and-practical-guidance
#15
REVIEW
Raffaella Casolino, Philip A Beer, Debyani Chakravarty, Melissa B Davis, Umberto Malapelle, Luca Mazzarella, Nicola Normanno, Chantal Pauli, Vivek Subbiah, Clare Turnbull, C Benedikt Westphalen, Andrew V Biankin
The last decade has seen rapid progress in the use of genomic tests, including gene panels, whole-exome sequencing, and whole-genome sequencing, in research and clinical cancer care. These advances have created expansive opportunities to characterize the molecular attributes of cancer, revealing a subset of cancer-associated aberrations called driver mutations. The identification of these driver mutations can unearth vulnerabilities of cancer cells to targeted therapeutics, which has led to the development and approval of novel diagnostics and personalized interventions in various malignancies...
January 4, 2024: CA: a Cancer Journal for Clinicians
https://read.qxmd.com/read/38720557/the-association-between-menopausal-hormone-therapy-and-breast-cancer-remains-unsettled
#16
JOURNAL ARTICLE
Mike Fillon
No abstract text is available yet for this article.
2024: CA: a Cancer Journal for Clinicians
https://read.qxmd.com/read/38720549/better-communication-is-key-for-quality-of-life-improvement-in-low-income-and-minority-patients
#17
JOURNAL ARTICLE
Mike Fillon
No abstract text is available yet for this article.
2024: CA: a Cancer Journal for Clinicians
https://read.qxmd.com/read/38481043/study-identifies-risk-factors-that-may-lead-to-secondary-cancers
#18
JOURNAL ARTICLE
Mike Fillon
No abstract text is available yet for this article.
2024: CA: a Cancer Journal for Clinicians
https://read.qxmd.com/read/38481032/is-mandated-genetic-counseling-needed
#19
JOURNAL ARTICLE
Mike Fillon
No abstract text is available yet for this article.
2024: CA: a Cancer Journal for Clinicians
https://read.qxmd.com/read/38240706/most-patients-with-cancer-are-not-undergoing-germline-genetic-testing
#20
JOURNAL ARTICLE
Mike Fillon
No abstract text is available yet for this article.
2024: CA: a Cancer Journal for Clinicians
journal
journal
20065
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.